Direct and indirect labeling with 99mTc of an antireceptor monoclonal antibody of EGF;Marcaje directo e indirecto con 99mTc de un anticuerpo monoclonal antireceptor del factor de crecimiento epidérmico

Revista Espanola de Medicina Nuclear

Volumn 24, Issue 1, 2005, Pages 38-44

  Calderon Sanchez O ^a   Zayas Crespo, F ^b   Leyva Montana R ^c   Beckford Vera, D ^c   Gomez J A ^d  

^a UNIVERSITY OF HAVANA   (Cuba)

^b Inst Nefrol   (Cuba)

^c Centro de Isotopos Cuba   (Cuba)

^d CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

EGF; Monoclonal antibody (MAb); Radiolabeling; Techetiunn 99m

Indexed keywords

ACID ANHYDRIDE; CHELATING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MERCAPTOETHANOL; MONOCLONAL ANTIBODY; PENTETIC ACID; TECHNETIUM 99M;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; DRUG STABILITY; FLOW CYTOMETRY; ISOTOPE LABELING; NONHUMAN; RAT; RAT STRAIN;

EID: 14644437758     PISSN: 02126982     EISSN: None     Source Type: Journal    
DOI: 10.1157/13070356     Document Type: Article

References (15)

1. Gano L, Patricio L, Marques E, Cantinho G, Pena H, Martins T, et al. Human polyclonal immunoglobulin labelled with technetium-99m via NHS-MAG3: a comparison of radiochemical behavior and biological efficacy with other labelling methods. Nucl Med Biol 1998;25:395-403.
2. 177Lu for radioimmunotherapeutic applications. Nucl Med Biol 2002;29:431-42.
3. 186Re-cMAb U36 radioimmunotherapy. J Nucl Med 2001;42:1364-7.
4. 111In-DOTA-Lanreotide Scintigraphy in Patients with Tumors of the Lung. J Nucl Med 2002;42:1309-15.
5. Hnatowich DJ. Is technetium-99m the radioisotope of choice for radioimmuno- scintigraphy. J Nucl Biol Med 1994;38(Suppl 4):22-32.
6. Morales A, Crespo FZ, Gandoff GN, Iznaga EN, Pérez NP, Hernández JC. Technetium-99m direct radiolabeling of monoclonal antibody ior egf/r3. Nucl Med Biol 1998;25:25-30.
7. Morales A, Nuñez-Gandoff G, Pérez NP, Véliz BC, Caballero I, Duconge J, et al. Freeze-dried formulations for direct 99mTc-labelling ior egf/r3 Mab: additives, biodistribution, and stability. Nucl Med Biol 1999;26:717-23.
8. Crombet T, Torres O, Neninger E, Catala M, Rodríguez N, Ramos M, et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor. Cancer Biother Radiopharm 2001;16:93-102.
9. Ramos M, Rodríguez N, Oliva JP, Iznaga N, Perera A, Morales A, et al. 99mTc-labeled antihuman epideramal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy. J Nucl Med 1999;40:768-75.
10. Seitz U, Neumaier B, Gdatting G, Kotzerke J, Bunjes D, Reske SN. Preparation and evaluation of the rhenium-188-labeled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukemia. Eur J Nucl Med 1999;26:1265-73.
11. Schwarz A, Steinstrasser A. A novel approach to 99mTc-labelled monoclonal antibodies (abstract). J Nucl Med 1987;28:721.
12. Eckelman WC, Karesh SM, Reba RC. New compounds: Fatty acids and long chain hydrocarbon derivatives containing a strong chelating agent. J Pharm Sci 1975;64:704-6.
13. Sakahara H, Endo K, Nakashima T, Koizumi M, Ohta H, Torizuka K, et al. Effect of DTPA Conjugation on the Antigen Binding Activity and Biodistribution of Monoclonal Antibodies Against alfa-Fetoprotein. J Nucl Med 1985;26:750-55.
14. Lanteigne D and Hnatowich DJ. The Labeling of DTPA-coupled Proteins with 99mTc. Int J Appl Radio Isot 1984;35:617-21.
15. 188Re-labeled Anti-epidermal Growth Factor Receptor Humanized Monoclonal Antibody h-R3: Labeling conditions, In vitro and In Vivo Stability. Methods Find Exp. Clin Pharmacol 2003;25(4).